| Date YYYY-MM-DD |
Board Meeting | Decision Point Number | Title |
|---|---|---|---|
| 2018-11-14 | B40 | GF/B40/DP01 |
Appointment of the Rapporteur Appointment of the Rapporteur
<p>Daniel Graymore from the United Kingdom constituency is designated as Rapporteur for the 40<sup>th</sup> Board Meeting.</p>
|
| 2018-11-14 | B40 | GF/B40/DP02 |
Approval of the Agenda Approval of the Agenda
<p>The agenda for the 40<sup>th</sup> Board Meeting (GF/B40/01 – Revision 1) is approved.</p>
|
| 2018-11-14 | B40 | GF/B40/DP03 |
2019 Work Plan and Budget Narrative and the 2019 Operating Expenses Budget 2019 Work Plan and Budget Narrative and the 2019 Operating Expenses Budget
<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the following: </p>
<ol>
<li>2019 Work Plan and Budget Narrative, as set forth in GF/B40/02A; and</li>
<li>The 2019 Operating Expenses Budget in the amount of USD 302 million, as set forth in GF/B40/02B (the “2019 OPEX Budget”), which:
<ol type="i">
<li>includes USD 15.59 million for the Office of the Inspector General’s 2019 operating expenses; and</li>
<li>remains within the total amount of USD 900 million available for operating expenses over the 2017-2019 period.</li>
</ol>
</li>
</ol>
|
| 2018-11-15 | B40 | GF/B40/DP04 |
Private Sector Engagement Private Sector Engagement
<p>The Board:</p>
<ol type="a">
<li>Recognizes the foundational concept of the Global Fund as an innovative public private partnership and the importance of the role of the private sector in the Global Fund’s resource mobilization strategy in providing both financial and non-financial resources to increase the scale and effectiveness of the Global Fund’s efforts to fight AIDS, tuberculosis and malaria;</li>
<li>Acknowledges the need to expand engagement with the private sector and takes note of the revision, by the Secretariat, of the Framework on Private Sector Engagement (the “Secretariat PSE Framework”) to provide balanced and robust operational policies and procedures which guide the Secretariat’s engagement approach;</li>
<li>Notes with appreciation the work undertaken by the Ethics and Governance Committee in overseeing and endorsing the Secretariat PSE Framework, and ensuring that a robust framework, which takes into account risk management and ethical and conflict of interest considerations, is in place to allow the Global Fund to continue to pursue appropriate and impactful engagement with the private sector; and</li>
<li>Confirms the importance of the role played by the private sector in the Global Fund’s resource mobilization strategy in providing both financial and non-financial resources to increase the scale and effectiveness of the Global Fund’s efforts to fight AIDS, tuberculosis and malaria.</li>
</ol>
|
| 2018-12-19 | B40 | GF/B40/EDP01 |
Appointment of a New Member to the Strategy Committee Appointment of a New Member to the Strategy Committee
<ol>
<li>The Board approves the appointment of Ms. Katja Roll, representing the German Constituency, as a voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</li>
</ol>
|
| 2018-12-21 | B40 | GF/B40/EDP02 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 to GF/B40/ER02 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2018-12-21 | B40 | GF/B40/EDP03 |
Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li>
<li>Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Pakistan malaria, as listed in Table 2 of GF/B40/ER02, based on available funding approved by the Audit and Finance Committee;</li>
<li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-01-31 | B40 | GF/B40/EDP04 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ER04 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-01-31 | B40 | GF/B40/EDP05 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER04 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-02-21 | B40 | GF/B40/EDP06 |
Approval of the Report of the 40th Board Meeting in Geneva Approval of the Report of the 40th Board Meeting in Geneva
<ol>
<li>The Board approves the Report of the 40th Board Meeting, as set forth in GF/B40/19.</li>
</ol>
|
| 2019-02-22 | B40 | GF/B40/EDP07 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B40/ER06 (“Table 1a” and “Table 1b”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
</ol>
<p>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>
|
| 2019-02-22 | B40 | GF/B40/EDP08 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER06 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-03-22 | B40 | GF/B40/EDP09 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ER07 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-03-22 | B40 | GF/B40/EDP10 |
Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER10 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-04-01 | B40 | GF/B40/EDP11 |
Amendments to the Operating Procedures of the Board and Committees of the Global Fund Amendments to the Operating Procedures of the Board and Committees of the Global Fund
<p>The Board approves the amendments to the Operating Procedures of the Board and Committees of the Global Fund as set forth in Annex 1 to GF/B40/ER08 which shall enter into force upon the approval of this electronic decision point.</p>
|
| 2019-04-19 | B40 | GF/B40/EDP12 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b of GF/B40/ER09 (“Table 1a” and “Table 1b”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-04-19 | B40 | GF/B40/EDP13 |
Decision on the Secretariat’s Recommendation on additional funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on additional funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER09 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-04-29 | B40 | GF/B40/EDP14 |
Revision to the Charter of the Office of the Inspector General Revision to the Charter of the Office of the Inspector General
<p><span>Based on the recommendation of the Audit and Finance Committee, the Board approves the Charter of the Office of the Inspector General, as revised and set forth in Annex 1 to GF/B40/ER10.</span></p>
|
| 2019-05-02 | B40 | GF/B40/EDP15 |
Appointment of the Board Chair and Vice-Chair Appointment of the Board Chair and Vice-Chair
<p><span>The Board appoints Dr Donald Kaberuka as Chair of the Board and Lady Roslyn Morauta as Vice-Chair of the Board to each serve two-year terms, or until the appointment of their respective successors, starting from the adjournment of the 41<sup>st</sup> Board Meeting on 16 May 2019.</span></p>
|
| 2019-05-13 | B40 | GF/B40/EDP16 |
Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B40/ER12 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2019-05-13 | B40 | GF/B40/EDP17 |
Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on integration of Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER12 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|